Active Surveillance Noninferior to BCG in High-Grade T1 Bladder Cancer
For Some Bladder Cancer Patients, Watching and Waiting Beats Treatment
This phase 3 randomized trial compared active surveillance with intravesical BCG in 263 patients with high-grade T1 bladder cancer and no re…
A major trial found that for certain bladder cancer patients who had all visible tumor removed, simply monitoring closely worked just as wel…
BCG plus mitomycin did not improve disease-free survival versus BCG alone in high-risk non-muscle-invasive bladder cancer patients
Adding mitomycin to bladder cancer treatment did not improve survival compared to bacillus calmette-guerin alone in this trial
This randomized Phase 3 trial enrolled 501 BCG-naive patients with high-grade pTa or any grade pT1 non-muscle-invasive bladder cancer. The s…
Doctors tested adding mitomycin to standard bladder cancer therapy. Patients receiving both drugs did not live longer without disease than t…
Systematic review and meta-analysis compares intravesical gemcitabine/docetaxel versus BCG for non-muscle-invasive bladder cancer
Gemcitabine and docetaxel show similar recurrence-free survival to BCG for bladder cancer
This systematic review and meta-analysis evaluated intravesical gemcitabine and docetaxel compared with Bacillus Calmette-Guérin (BCG) in pa…
A meta-analysis of 1634 patients found gemcitabine and docetaxel offered recurrence-free survival rates comparable to BCG therapy for non-mu…
Narrative review advocates multi-omics models to clarify exercise associations
Exercise links to health benefits, but direct causation remains associative
This narrative review discusses the complex relationship between exercise and health outcomes.
A narrative review suggests exercise connects to health outcomes, though direct causation remains associative and knowledge gaps persist.
Adjuvant intravesical BCG versus Epirubicin in intermediate-risk non-muscle invasive bladder cancer
A Common Bladder Cancer Treatment Extends Remission, But at a Cost
This randomized controlled trial compared adjuvant intravesical BCG and Epirubicin in 122 patients with intermediate-risk non-muscle invasiv…
For a common bladder cancer, one treatment keeps the disease away longer, but the other may offer a better daily life.